<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148041">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01974687</url>
  </required_header>
  <id_info>
    <org_study_id>IDX-04B-001</org_study_id>
    <secondary_id>U1111-1149-5611</secondary_id>
    <nct_id>NCT01974687</nct_id>
  </id_info>
  <brief_title>Study Assessing Single and Multiple Doses of IDX21437 in Healthy and HCV-Infected Subjects</brief_title>
  <official_title>A Phase I/IIa Study Assessing Single and Multiple Doses of IDX21437 in Healthy and HCV-Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idenix Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idenix Pharmaceuticals</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-part study to evaluate the safety, tolerability and PK of IDX21437 in healthy and
      HCV-infected subjects.  The effect of food on the PK of IDX21437 will be evaluated.
      Antiviral activity will also be assessed in HCV-infected subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability assessment</measure>
    <time_frame>up to 35 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Proportion of subjects experiencing adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic</measure>
    <time_frame>Up to 120 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma and urine concentrations of IDX21437 and its metabolite/s.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Antiviral activity</measure>
    <time_frame>Up to 35 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in plasma HCV RNA and emergence of resistance mutations</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects, sequential dose escalation, IDX21437 capsules or Matching Placebo capsules, once daily, for 1 or 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV subjects genotype 1, IDX21437 capsules, once for 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV subjects genotype 1, IDX21437 capsules or Matching Placebo capsules, once daily, for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV subjects genotypes 2 to 6, IDX21437 capsules, once daily, for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV subject genotype 1, IDX21437 capsules, once daily, for 1 day or for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDX21437</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects

          -  Subjects are in good general health.

          -  Subjects have provided written informed consent form.

          -  All subjects of childbearing potential must have agreed to use a double method of
             birth control (one of which must be a barrier) from Screening through at least 90
             days after the last dose of the study drug.

        HCV Subjects

          -  Documented clinical history compatible with chronic hepatitis C.

          -  Treatment-na√Øve

          -  HCV Genotype 1, 2, 3, 4, 5 or 6

        Exclusion Criteria:

        All subjects

          -  Pregnant or breastfeeding

          -  Co-infected with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV).

          -  Decompensated liver disease

          -  Other clinically significant medical conditions or laboratory abnormalities.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John Z Sullivan-Bolyai, MD</last_name>
    <phone>877-433-6491</phone>
    <email>clinicaltrials@idenix.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 1, 2013</lastchanged_date>
  <firstreceived_date>October 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C virus</keyword>
  <keyword>HCV</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
